 "drugs, pharma, prices, drug prices, medicines, health")
Drug major Cipla on Monday said it has inked a licensing pact with Novartis Pharma AG to manufacture and market Galvus range, used in the treatment of type 2 diabetes, from January 1, 2026.
The Mumbai-based company has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) to manufacture and market Galvus and Galvus combination brands, it said in a regulatory filing.
"This deal is expected to further bolster Cipla's position in India as one of the top players in the diabetes category," it added.
The agreement is subject to satisfaction of certain conditions precedent, the drug firm said.
Galvus is one of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space and amongst the prominent brands in the oral diabetic medication category, the drug firm stated.
On Monday, shares of Cipla ended 1.02 per cent up at Rs 901.85 apiece on the BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
